The information on this site is intended for US healthcare professionals and clinical staff only.
ZYDELIG® is the most
prescribed PI3K inhibitor*
*IntrinsiQ, May 2015 - November 2018, IMS XPO
and IMS DDD data, October 2018-March 2019.
Updated results from finalanalysis of the pivotal trial View efficacy
ZYDELIG is a PI3Kδ inhibitor indicated for
Accelerated approval was granted for follicular lymphoma and SLL based on overall response rate. An improvement in patient survival or disease-related symptoms has not been established. Continued approval for these indications may be contingent upon verification of clinical benefit in confirmatory trials.
ZYDELIG is not indicated or recommended for first-line treatment of any patient or in combination with bendamustine and/or rituximab for the treatment of follicular lymphoma.